The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1088 Ozempic articles
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
Weight-loss injections like Ozempic and Wegovy, containing semaglutide, may protect the heart from severe tissue damage after a heart attack, according to new research. The study reveals how this GLP-1 medication prevents the dangerous 'no-reflow' phenomenon. Experts suggest it could even be administered by paramedics en route to the hospital.
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
A man who shed six stone on Mounjaro shares his dramatic transformation from 123kg, but warns of 'horrible' side effects like chronic vomiting and dehydration no one mentioned. Despite the challenges, he reduced hypertension meds and gained food control. Discover his full story and management strategies.
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
New research tracking nearly 150,000 people on GLP-1 medications like Ozempic and Wegovy suggests higher risks of osteoporosis, gout, and osteomalacia over five years. While not proving causation, the study highlights potential impacts on bone and joint health from rapid weight loss. Experts emphasize nutrition, exercise, and monitoring to mitigate risks.
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.
